- Last sale
- Nov 12, 2026 · -0.06%
- Market cap
- $2.00B
- 259.94M shares
- Filings
- 426
Q3 2026−28.3% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−32.7% FY25 yoy
- $2.00B
- —
- 9.4×
- 10.2×
- -0.66%
- —
Twelve months to Sep 30, 2026 · derived
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $185,743,000 | reported | |
| FY 2024 | 2024-12-31 | $259,185,000 | reported | |
| FY 2023 | 2023-12-31 | $288,945,000 | reported | |
| FY 2022 | 2022-12-31 | $883,001,000 | reported | |
| FY 2021 | 2021-12-31 | $799,240,000 | reported | |
| FY 2020 | 2020-12-31 | $284,098,000 | reported | |
| FY 2019 | 2019-12-31 | $143,140,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2022 | — | $0.00 | $0.00 | — | — | — | 0.0% |
| FY2021 | — | $0.00 | $0.00 | — | — | — | 0.0% |
| FY2020 | — | $33.66M | $33.66M | — | — | — | 26.5% |
| FY2019 | — | $0.00 | $0.00 | — | — | — | 0.0% |
Segments
LineFY2025ShareChange
TriLink$119.79M64%−39.0%
Cygnus$65.96M36%+5.0%
Biologics Safety Testing———
Nucleic Acid Production———
Protein Detection———
Total$185.74M
Maravai Lifesciences Holdings, Inc. · CIK 1823239 · Engraved from SEC EDGAR